Annual EBITDA
-$24.04 M
-$2.25 M-10.32%
31 December 2023
Summary:
Lineage Cell Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$24.04 million, with the most recent change of -$2.25 million (-10.32%) on 31 December 2023. During the last 3 years, it has risen by +$367.00 thousand (+1.50%). LCTX annual EBITDA is now -3334.43% below its all-time high of -$700.00 thousand, reached on 30 June 1992.LCTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.70 M
+$2.03 M+35.39%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.70 million, with the most recent change of +$2.03 million (+35.39%) on 30 September 2024. Over the past year, it has increased by +$2.83 million (+43.35%). LCTX quarterly EBITDA is now -312.16% below its all-time high of $1.74 million, reached on 31 December 2009.LCTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$22.10 M
+$2.83 M+11.35%
30 September 2024
Summary:
Lineage Cell Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$22.10 million, with the most recent change of +$2.83 million (+11.35%) on 30 September 2024. Over the past year, it has increased by +$2.22 million (+9.14%). LCTX TTM EBITDA is now -44540.40% below its all-time high of -$49.50 thousand, reached on 31 March 2004.LCTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -10.3% | +43.4% | +9.1% |
| 3 y3 years | +1.5% | +44.3% | +14.5% |
| 5 y5 years | +36.3% | +51.7% | +43.6% |
LCTX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -10.3% | +50.3% | at high | +86.8% | -1.4% | +54.3% |
| 5 y | 5 years | -10.3% | +50.3% | at high | +86.8% | -1.4% | +54.3% |
| alltime | all time | -3334.4% | +59.6% | -312.2% | +86.8% | <-9999.0% | +68.8% |
Lineage Cell Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.70 M(-35.4%) | -$22.10 M(-11.4%) |
| June 2024 | - | -$5.72 M(-11.7%) | -$24.93 M(+3.6%) |
| Mar 2024 | - | -$6.49 M(+4.8%) | -$24.06 M(+0.1%) |
| Dec 2023 | -$24.04 M(+10.3%) | -$6.19 M(-5.2%) | -$24.04 M(-1.1%) |
| Sept 2023 | - | -$6.53 M(+34.5%) | -$24.32 M(+6.4%) |
| June 2023 | - | -$4.85 M(-25.0%) | -$22.85 M(+3.6%) |
| Mar 2023 | - | -$6.47 M(+0.1%) | -$22.05 M(+1.2%) |
| Dec 2022 | -$21.79 M(-54.9%) | -$6.47 M(+27.8%) | -$21.79 M(-49.8%) |
| Sept 2022 | - | -$5.06 M(+24.9%) | -$43.37 M(-3.5%) |
| June 2022 | - | -$4.05 M(-34.9%) | -$44.96 M(-5.9%) |
| Mar 2022 | - | -$6.22 M(-77.8%) | -$47.79 M(-1.1%) |
| Dec 2021 | -$48.34 M(+98.0%) | -$28.05 M(+322.1%) | -$48.34 M(+87.1%) |
| Sept 2021 | - | -$6.64 M(-3.5%) | -$25.84 M(+1.4%) |
| June 2021 | - | -$6.88 M(+1.8%) | -$25.47 M(+4.2%) |
| Mar 2021 | - | -$6.76 M(+22.0%) | -$24.44 M(+0.1%) |
| Dec 2020 | -$24.41 M(-32.0%) | -$5.55 M(-11.6%) | -$24.41 M(-2.4%) |
| Sept 2020 | - | -$6.28 M(+7.1%) | -$25.00 M(-5.2%) |
| June 2020 | - | -$5.86 M(-12.9%) | -$26.39 M(-13.8%) |
| Mar 2020 | - | -$6.73 M(+9.6%) | -$30.60 M(-14.7%) |
| Dec 2019 | -$35.88 M(-4.9%) | -$6.14 M(-19.9%) | -$35.88 M(-8.5%) |
| Sept 2019 | - | -$7.66 M(-23.9%) | -$39.21 M(-4.6%) |
| June 2019 | - | -$10.07 M(-16.1%) | -$41.10 M(+4.5%) |
| Mar 2019 | - | -$12.01 M(+26.8%) | -$39.31 M(+3.9%) |
| Dec 2018 | -$37.72 M(+1.0%) | -$9.47 M(-0.8%) | -$37.83 M(+2.1%) |
| Sept 2018 | - | -$9.55 M(+15.3%) | -$37.06 M(+2.4%) |
| June 2018 | - | -$8.28 M(-21.3%) | -$36.19 M(-3.3%) |
| Mar 2018 | - | -$10.52 M(+20.9%) | -$37.44 M(+0.2%) |
| Dec 2017 | -$37.36 M(-31.1%) | -$8.70 M(+0.2%) | -$37.36 M(-4.4%) |
| Sept 2017 | - | -$8.68 M(-8.9%) | -$39.08 M(+0.0%) |
| June 2017 | - | -$9.53 M(-8.7%) | -$39.07 M(-8.4%) |
| Mar 2017 | - | -$10.44 M(+0.2%) | -$42.64 M(-21.3%) |
| Dec 2016 | -$54.21 M(-8.9%) | -$10.43 M(+20.3%) | -$54.21 M(-15.1%) |
| Sept 2016 | - | -$8.66 M(-33.9%) | -$63.87 M(-9.7%) |
| June 2016 | - | -$13.11 M(-40.5%) | -$70.73 M(+1.7%) |
| Mar 2016 | - | -$22.02 M(+9.6%) | -$69.56 M(+17.0%) |
| Dec 2015 | -$59.48 M(+40.7%) | -$20.08 M(+29.4%) | -$59.47 M(+18.3%) |
| Sept 2015 | - | -$15.53 M(+30.1%) | -$50.27 M(+11.1%) |
| June 2015 | - | -$11.93 M(+0.1%) | -$45.24 M(+1.1%) |
| Mar 2015 | - | -$11.93 M(+9.5%) | -$44.74 M(+5.7%) |
| Dec 2014 | -$42.27 M(+22.3%) | -$10.89 M(+3.7%) | -$42.33 M(+1.6%) |
| Sept 2014 | - | -$10.50 M(-8.1%) | -$41.67 M(+2.7%) |
| June 2014 | - | -$11.43 M(+20.1%) | -$40.56 M(+11.2%) |
| Mar 2014 | - | -$9.51 M(-7.0%) | -$36.47 M(+5.5%) |
| Dec 2013 | -$34.57 M(+56.0%) | -$10.23 M(+8.9%) | -$34.58 M(+12.9%) |
| Sept 2013 | - | -$9.39 M(+28.1%) | -$30.62 M(+15.8%) |
| June 2013 | - | -$7.33 M(-3.8%) | -$26.44 M(+7.9%) |
| Mar 2013 | - | -$7.62 M(+21.5%) | -$24.50 M(+10.5%) |
| Dec 2012 | -$22.17 M(+35.8%) | -$6.27 M(+20.5%) | -$22.17 M(+6.2%) |
| Sept 2012 | - | -$5.21 M(-3.5%) | -$20.88 M(+8.8%) |
| June 2012 | - | -$5.40 M(+2.0%) | -$19.19 M(+5.9%) |
| Mar 2012 | - | -$5.29 M(+6.2%) | -$18.12 M(+10.9%) |
| Dec 2011 | -$16.32 M(+82.9%) | -$4.98 M(+41.8%) | -$16.34 M(+12.2%) |
| Sept 2011 | - | -$3.52 M(-18.9%) | -$14.56 M(+9.7%) |
| June 2011 | - | -$4.33 M(+23.6%) | -$13.28 M(+19.5%) |
| Mar 2011 | - | -$3.50 M(+9.1%) | -$11.11 M(+24.5%) |
| Dec 2010 | -$8.92 M(+156.0%) | -$3.21 M(+43.8%) | -$8.92 M(+124.8%) |
| Sept 2010 | - | -$2.23 M(+3.1%) | -$3.97 M(-14.9%) |
| June 2010 | - | -$2.17 M(+64.8%) | -$4.66 M(+29.7%) |
| Mar 2010 | - | -$1.31 M(-175.4%) | -$3.60 M(+12.9%) |
| Dec 2009 | -$3.49 M(+24.2%) | $1.74 M(-159.6%) | -$3.18 M(-45.9%) |
| Sept 2009 | - | -$2.93 M(+166.1%) | -$5.89 M(+51.9%) |
| June 2009 | - | -$1.10 M(+21.7%) | -$3.88 M(+6.3%) |
| Mar 2009 | - | -$903.10 K(-5.9%) | -$3.65 M(+17.6%) |
| Dec 2008 | -$2.81 M | -$959.60 K(+5.0%) | -$3.10 M(+29.3%) |
| Sept 2008 | - | -$913.90 K(+5.2%) | -$2.40 M(+46.9%) |
| June 2008 | - | -$869.00 K(+143.6%) | -$1.63 M(+55.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2008 | - | -$356.70 K(+38.6%) | -$1.05 M(-12.6%) |
| Dec 2007 | -$1.22 M(-29.2%) | -$257.40 K(+73.2%) | -$1.20 M(-6.4%) |
| Sept 2007 | - | -$148.60 K(-48.1%) | -$1.28 M(-4.8%) |
| June 2007 | - | -$286.30 K(-43.6%) | -$1.35 M(-20.4%) |
| Mar 2007 | - | -$507.90 K(+49.3%) | -$1.69 M(+2.9%) |
| Dec 2006 | -$1.73 M(-14.2%) | -$340.10 K(+59.7%) | -$1.65 M(-6.8%) |
| Sept 2006 | - | -$213.00 K(-66.3%) | -$1.77 M(-9.7%) |
| June 2006 | - | -$632.30 K(+37.6%) | -$1.96 M(+11.8%) |
| Mar 2006 | - | -$459.60 K(-0.3%) | -$1.75 M(-13.1%) |
| Dec 2005 | -$2.01 M(+118.7%) | -$460.90 K(+14.4%) | -$2.01 M(-6.2%) |
| Sept 2005 | - | -$402.80 K(-5.4%) | -$2.14 M(-0.2%) |
| June 2005 | - | -$425.70 K(-41.1%) | -$2.15 M(-0.5%) |
| Mar 2005 | - | -$722.60 K(+21.7%) | -$2.16 M(+134.9%) |
| Dec 2004 | -$920.00 K(+4.6%) | -$593.70 K(+45.7%) | -$920.00 K(+103.0%) |
| Sept 2004 | - | -$407.60 K(-6.8%) | -$453.10 K(+141.7%) |
| June 2004 | - | -$437.40 K(-184.3%) | -$187.50 K(+278.8%) |
| Mar 2004 | - | $518.70 K(-509.1%) | -$49.50 K(-94.4%) |
| Dec 2003 | -$879.20 K(-42.5%) | -$126.80 K(-10.7%) | -$879.20 K(-27.6%) |
| Sept 2003 | - | -$142.00 K(-52.6%) | -$1.22 M(+14.2%) |
| June 2003 | - | -$299.40 K(-3.7%) | -$1.06 M(-20.5%) |
| Mar 2003 | - | -$311.00 K(-32.8%) | -$1.34 M(-7.8%) |
| Dec 2002 | -$1.53 M(-52.2%) | -$462.80 K(-5023.4%) | -$1.45 M(+23.0%) |
| Sept 2002 | - | $9400.00(-101.6%) | -$1.18 M(-44.0%) |
| June 2002 | - | -$573.30 K(+35.1%) | -$2.11 M(-20.3%) |
| Mar 2002 | - | -$424.40 K(+121.7%) | -$2.64 M(-16.3%) |
| Dec 2001 | -$3.20 M(-36.2%) | -$191.40 K(-79.1%) | -$3.15 M(-20.8%) |
| Sept 2001 | - | -$916.10 K(-17.4%) | -$3.98 M(-8.1%) |
| June 2001 | - | -$1.11 M(+18.1%) | -$4.33 M(-5.3%) |
| Mar 2001 | - | -$938.70 K(-8.1%) | -$4.58 M(-8.5%) |
| Dec 2000 | -$5.01 M(-12.0%) | -$1.02 M(-19.4%) | -$5.00 M(-8.1%) |
| Sept 2000 | - | -$1.27 M(-6.4%) | -$5.44 M(-17.2%) |
| June 2000 | - | -$1.35 M(-0.6%) | -$6.57 M(+4.0%) |
| Mar 2000 | - | -$1.36 M(-6.7%) | -$6.32 M(+9.7%) |
| Dec 1999 | -$5.70 M(+137.5%) | -$1.46 M(-39.2%) | -$5.76 M(+33.9%) |
| Sept 1999 | - | -$2.40 M(+118.2%) | -$4.30 M(+38.7%) |
| June 1999 | - | -$1.10 M(+37.5%) | -$3.10 M(+21.6%) |
| Mar 1999 | - | -$800.00 K(-33.3%) | -$2.55 M(-33.8%) |
| Dec 1998 | -$2.40 M(-34.2%) | - | - |
| Sept 1998 | - | -$1.20 M(+118.2%) | -$3.85 M(+2.7%) |
| June 1998 | - | -$550.00 K(-54.2%) | -$3.75 M(-14.8%) |
| June 1998 | -$3.65 M(+14.1%) | - | - |
| Mar 1998 | - | -$1.20 M(+33.3%) | -$4.40 M(+18.9%) |
| Dec 1997 | - | -$900.00 K(-18.2%) | -$3.70 M(+5.7%) |
| Sept 1997 | - | -$1.10 M(-8.3%) | -$3.50 M(+16.7%) |
| June 1997 | -$3.20 M(+60.0%) | -$1.20 M(+140.0%) | -$3.00 M(-23.1%) |
| Mar 1997 | - | -$500.00 K(-28.6%) | -$3.90 M(+18.2%) |
| Dec 1996 | - | -$700.00 K(+16.7%) | -$3.30 M(+32.0%) |
| Sept 1996 | - | -$600.00 K(-71.4%) | -$2.50 M(+8.7%) |
| June 1996 | -$2.00 M(-20.0%) | -$2.10 M(-2200.0%) | -$2.30 M(+130.0%) |
| Mar 1996 | - | $100.00 K(0.0%) | -$1.00 M(-37.5%) |
| Dec 1995 | - | $100.00 K(-125.0%) | -$1.60 M(-30.4%) |
| Sept 1995 | - | -$400.00 K(-50.0%) | -$2.30 M(0.0%) |
| June 1995 | -$2.50 M(+56.3%) | -$800.00 K(+60.0%) | -$2.30 M(+9.5%) |
| Mar 1995 | - | -$500.00 K(-16.7%) | -$2.10 M(+16.7%) |
| Dec 1994 | - | -$600.00 K(+50.0%) | -$1.80 M(+20.0%) |
| Sept 1994 | - | -$400.00 K(-33.3%) | -$1.50 M(+7.1%) |
| June 1994 | -$1.60 M(+23.1%) | -$600.00 K(+200.0%) | -$1.40 M(+16.7%) |
| Mar 1994 | - | -$200.00 K(-33.3%) | -$1.20 M(0.0%) |
| Dec 1993 | - | -$300.00 K(0.0%) | -$1.20 M(0.0%) |
| Sept 1993 | - | -$300.00 K(-25.0%) | -$1.20 M(+9.1%) |
| June 1993 | -$1.30 M(+85.7%) | -$400.00 K(+100.0%) | -$1.10 M(0.0%) |
| Mar 1993 | - | -$200.00 K(-33.3%) | -$1.10 M(+10.0%) |
| Dec 1992 | - | -$300.00 K(+50.0%) | -$1.00 M(+42.9%) |
| Sept 1992 | - | -$200.00 K(-50.0%) | -$700.00 K(+40.0%) |
| June 1992 | -$700.00 K | -$400.00 K(+300.0%) | -$500.00 K(+400.0%) |
| Mar 1992 | - | -$100.00 K | -$100.00 K |
FAQ
- What is Lineage Cell Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual EBITDA year-on-year change?
- What is Lineage Cell Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly EBITDA year-on-year change?
- What is Lineage Cell Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics TTM EBITDA year-on-year change?
What is Lineage Cell Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of LCTX is -$24.04 M
What is the all time high annual EBITDA for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$700.00 K
What is Lineage Cell Therapeutics annual EBITDA year-on-year change?
Over the past year, LCTX annual earnings before interest, taxes, depreciation & amortization has changed by -$2.25 M (-10.32%)
What is Lineage Cell Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of LCTX is -$3.70 M
What is the all time high quarterly EBITDA for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.74 M
What is Lineage Cell Therapeutics quarterly EBITDA year-on-year change?
Over the past year, LCTX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$2.83 M (+43.35%)
What is Lineage Cell Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of LCTX is -$22.10 M
What is the all time high TTM EBITDA for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$49.50 K
What is Lineage Cell Therapeutics TTM EBITDA year-on-year change?
Over the past year, LCTX TTM earnings before interest, taxes, depreciation & amortization has changed by +$2.22 M (+9.14%)